Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Sarepta Therapeutics (SRPT.O) shares surged 59% in extended trading after the company announced it would resume shipping its gene therapy, Elevidys, to ambulatory patients. This decision follows an FDA recommendation to lift a voluntary shipping halt, as a probe determined an 8-year-old's death was unrelated to the treatment. While this significantly improves Elevidys' near-term sales outlook for ambulatory use, the FDA maintains a hold on the therapy for non-ambulatory patients, continuing investigations into other patient deaths, signaling ongoing regulatory oversight.

Analysis

Sarepta Therapeutics has received a significant positive catalyst with the U.S. FDA's recommendation to resume shipping its gene therapy, Elevidys, for ambulatory patients. This development, which followed a determination that a patient death in Brazil was unrelated to the treatment, directly addresses a major commercial overhang and triggered a 59% surge in the company's extended-hours trading, reflecting substantial investor relief. According to a Jefferies analyst, the event significantly improves the near-term sales outlook, with only a modest impact anticipated for third-quarter results due to the short one-week shipping pause. However, a critical risk remains as the therapy's use is still on hold for non-ambulatory patients. The FDA is continuing its investigation into the deaths of two patients in this cohort, meaning Sarepta still faces intense regulatory scrutiny that could impact the therapy's broader market potential and future label expansions.

Key Decisions for Investors

• Investors should recognize the partial de-risking of Elevidys, as the resumption of shipments to the ambulatory population secures a key near-term revenue stream and justifies a more positive re-evaluation of the company's sales outlook.
• It is crucial to closely monitor any updates from the FDA's ongoing investigation into patient deaths in the non-ambulatory cohort, as the outcome represents a major binary event for the therapy's total addressable market.
• Given the 59% stock price increase on this news, consider trimming positions to lock in profits, while being aware that unresolved regulatory issues for the non-ambulatory group will likely fuel future volatility.